valu usd unless otherwis note
pullback present buy opportun ahead
view among select group large-cap med-tech compani
coverag univers gener organ revenu growth
low- mid-teen ep growth exclud fx oper
risk factor stronger dollar tax rate manag
therefor sell-off first trade day vs
 buy opportun
manag currenc volatil noth new
approxim abt ww revenu deriv intern
larg emerg market presenc establish
pharmaceut divis illustr well handl
fx volatil first issu guidanc forecast
currenc would contribut ww revenu growth
current guidanc updat earn call fx
modestli reduc revenu growth unfavor swing
bp howev abt current ep guidanc
toward upper end initi guidanc
expect anoth year organ revenu growth
estim base high-single-digit forecast medic
devic epd mid/high-single-digit growth diagnost
structur heart electrophysiolog diabet primari
growth driver medic devic potenti better result
neuromodul heart failur diabet work
number product enhanc help maintain/extend
leadership posit cgm character alin
instrument suit multi-year growth engin compani drive
adopt exist new custom
initi ep guidanc like includ consensu call
manag express confid mid-teen cc ep growth
suggest fx headwind estim reason start
earn power higher figur fx volatil suggest
conservat initi guid sever med-tech compani
highlight fx major headwind ep growth especi
adjust estim due fx higher tax rate assumpt
sinc mid-octob dollar appreci versu euro
british pound depreci versu yen among emerg
market currenc dollar weaken indian rupe
strengthen versu rubl reassess abt fx exposur
lead us revis estim currency-rel revenu
headwind prior estim also increas
assumpt effect tax rate bp follow
recent remark sever manag team topic
revis estim old
estim old
price prior trade day market close estimate unless otherwis note
cours high-single-digit revenu growth
double-digit ep growth product cycl
refresh medic devic diagnost cost synergi
stj alr capit deploy acceler
debt repay push abt revenu ep growth
ahead sever med-tech peer revenu estim
impli cc revenu growth
believ upsid estim
ep estim repres low double-digit
freestyl libr repres major sourc upsid us
launch strong start growth
continu rapid pace recent eu approv freestyl
libr catalyst approv expect
next year estim ww sale cross
reach close
mitraclip sustain sale growth next
year highli success coapt trial secondari mr
patient open therapi much bigger patient
popul coapt result may also requir chang
on-going trial competitor devic benefit
momentum diagnost continu least
next coupl year alr transact ad
diagnost portfolio receiv fda
approv first two instrument new alin
platform laboratori diagnost other
forthcom alin suit gain good
traction europ five six instrument
commerci avail instrument drive
sustain recoveri pediatr nutrit return
segment mid-single-digit revenu growth
addit establish pharmaceut maintain
cc growth led double-digit growth emerg
bloomberg capit market estim upside/downside/target
arriv price target use sum-of-the-
part analysi valu report segment individu
use respect ev/ebitda multipl blend ev/
ebitda multipl ebitda estim
billion yield target key assumpt underli
valuat cc revenu growth cc
growth basi point increas oper
margin year continu debt reduct
 price target impli price-to-earnings multipl
ep estim
arriv upsid scenario ev/ebitda multipl
ebitda estim billion key
differ base-cas assumpt cc
revenu growth basi point ebit
margin expans year due higher revenu growth
faster realiz cost synergi integr
stj alr capit deploy share repurchas
tuck-in acquisit
downsid scenario ebitda
billion key differ base-cas assumpt
mid-single-digit cc organ revenu growth
basi point ebit margin expans
year due slower revenu growth slower
realiz cost synergi
sum-of-the-part valuat abt five major busi base ebitda estim
yield price target individu ev/ebitda multipl use valuat
establish pharmaceut multipl along ebitda
estim busi give blend ev/ebitda estim consolid ebitda
billion target impli multipl ep estim
share current trade around ep estim price target
basi outperform rate
risk rate price target
face risk typic global diversifi healthcar compani impedi
price target rate includ competit currenc patent litig reimburs
clinic trial risk navig fda prolong econom slump
abbott laboratori one diversifi health care product compani
world product encompass intern brand gener drug devic diagnost
except ep fy dec
